Clinical Trial

Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis

Recruiting
View on ClinicalTrials.gov →
Summary
Patients of cirrhosis aged 18 to 75 years who have no esophageal varices will be enrolled. After baseline evaluation, the participants will be randomized to receive either Placebo or Carvedilol 12.5 mg BD. After randomization they will be followed up for one year.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2010-09-29; most recent amendment 2025-08-12.
Trial Details
NCT Number NCT01212250
Lead Sponsor Institute of Liver and Biliary Sciences, India
Conditions Cirrhosis
Enrollment 132 participants
Start Date 2010-09-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-13